A $29 Billion Listing Caps the Strongest First-Half Issuance Since 2021 — What the Pipeline Says About H2

The IPO market enters July 2026 with more momentum than at any point since the 2021 cycle — and a single deal threatens to dwarf everything that came before it. SK hynix, the world’s second-largest memory chipmaker, is expected to list American depositary receipts on the Nasdaq on July 10 under the symbol SKHY, aiming to raise up to $29 billion from 17.79 million new shares{{cite:chatcmpltool}}. At the top of its range, that would rank as the largest ADR offering in history, surpassing Alibaba’s $21.8 billion New York debut{{cite:chatcmpltool}}. The deal is managed by BofA Securities, Citigroup, Goldman Sachs, and J.P. Morgan{{cite:chatcmpltool}}.

It arrives on the heels of a first half that saw 82 IPOs priced in the United States, raising $114.7 billion — a 635% jump in proceeds versus the same period in 2025{{cite:chatcmpltool}}. Total U.S. equity capital markets proceeds topped $120 billion year-to-date through June, the strongest first-half pace since 2021{{cite:chatcmpltool}}. The pipeline behind that is the deepest in years: 137 IPOs have been filed YTD, up 11.4% from last year{{cite:chatcmpltool}}.

The SK hynix Deal: AI Memory Meets U.S. Capital

SK hynix holds approximately 60% of the global high-bandwidth memory (HBM) market, the component layer most directly exposed to the AI accelerator buildout{{cite:chatcmpltool}}. The company’s shares have surged over 280% year-to-date on the Korean exchange, pushing its market capitalization above $1 trillion{{cite:chatcmpltool}}. The ADR proceeds are earmarked for capacity expansion, including the Yongin semiconductor cluster in South Korea — set to begin coming online in 2027 — and a $4 billion packaging plant in Indiana, the company’s first U.S. manufacturing footprint{{cite:chatcmpltool}}.

What makes this listing structurally distinctive is that it is not a traditional IPO. SK hynix is already publicly traded in Seoul (000660.KS); the Nasdaq listing creates a parallel U.S.-traded access point via ADRs rather than a fresh primary offering of a private company. The capital raised is primary — new shares issued by the company — but the investor base expansion is the strategic logic, not price discovery. In SK hynix’s own words, the listing should allow its “true corporate value to be properly evaluated” by broadening touchpoints in the United States, “the epicenter of AI technological innovation”{{cite:chatcmpltool}}.

The risk concentration is worth flagging: Samsung Electronics and SK hynix together account for more than 40% of South Korea’s benchmark Kospi, a level that has raised concerns about market exposure to supply chain disruptions or a slowdown in global data center investment{{cite:chatcmpltool}}. A successful Nasdaq listing could partially redistribute that concentration — or amplify it if U.S. AI sentiment turns.

SpaceX: The Lockup Clock Everyone Is Watching

The other gravitational center of the new-issuance market is SpaceX (SPCX), which went public on June 12 at $135 per share, opening at $150 and surging to an intraday peak of $225.64 on June 16 before retracing{{cite:chatcmpltool}}. The IPO raised $85.7 billion in cash and initially valued the company at $1.77 trillion{{cite:chatcmpltool}}. As of the July 2 close, SPCX traded at $162.00, up 2.83% on the day but roughly 28% below its June 16 high{{cite:chatcmpltool}}.

The 180-day lockup on most insider shares expires December 8, 2026, with the first selling window opening after Q2 earnings in late July or August{{cite:chatcmpltool}}. Elon Musk’s 6.4 billion shares — roughly 42% of the company — remain locked until June 12, 2027{{cite:chatcmpltool}}. That staggered release schedule means the market will absorb incremental supply over roughly a year, not all at once. But the December 8 unlock for non-Musk insiders is the date the market is already pricing in.

The SpaceX aftermath matters for the broader IPO market because it is the single largest test of post-debut liquidity absorption in history. If the stock stabilizes through its lockup window, it validates the thesis that the market can absorb record issuance without a supply shock. If it rolls over as unlocks approach, it creates a cautionary template that could chill the H2 pipeline.

The July Calendar: SPACs and Small Deals, Then SK hynix

Beyond SK hynix, the July IPO calendar is thin on marquee names. The near-term pipeline is dominated by blank-check companies: Meridian3 Industrials Acquisition (MIACU, $175 million) and Viking Acquisition Corp II (VII.U, $200 million) both priced on July 2{{cite:chatcmpltool}}. The week of July 6 brings Coolbit Technologies (CBAI, ~$22.5M), a MetaOptics uplisting (MOT, ~$18M), and Riku Dining Group (RIKU, ~$25M), followed by Tarsier Pharma (TARX, ~$45M) on July 9{{cite:chatcmpltool}}.

The SPAC cycle is running at roughly four times the 2025 pace — about 80 SPAC IPOs through April raised ~$14 billion — but this cycle is concentrated among institutional-grade sponsors with performance-based promotes and committed PIPE financing{{cite:chatcmpltool}}. The pressure on existing vehicles is acute: of 352 active SPACs with 111 pending de-SPAC transactions, only 11 have closed year-to-date, and redemption rates exceed 95%{{cite:chatcmpltool}}. An estimated 25–35% of active SPACs will likely extend or liquidate as their trust clocks tick down{{cite:chatcmpltool}}.

Renaissance Capital’s latest pipeline filings show new SPACs continuing to enter: B&R Technology Merger filed for a $325 million IPO targeting tech with AI tailwinds, Laris Growth Acquisition filed for $200 million targeting quantum computing, and Gold Mountain Acquisition filed for $75 million targeting Asian businesses — all in the first days of July{{cite:chatcmpltool}}.

Gross Issuance vs. Net Supply: The Buyback Offset

The headline issuance numbers are large enough to prompt a natural question: does record supply become a headwind? UBS’s answer is no, and the reasoning rests on a distinction between gross and net equity supply.

UBS estimates IPO issuance on track to reach $200–350 billion this year, with secondary offerings potentially exceeding $400 billion — both record highs in absolute terms{{cite:chatcmpltool}}. But U.S. share buybacks totaled $1.2 trillion over the past 12 months, and UBS expects repurchases to remain near that level{{cite:chatcmpltool}}. The implication: the corporate sector will likely buy back slightly more stock than it issues, meaning net equity supply could still shrink even as gross issuance hits records{{cite:chatcmpltool}}.

UBS also notes that when measured relative to total U.S. equity market capitalization of approximately $72 trillion, estimated annual issuance is only slightly above the long-term average as a percentage of the Russell 3000 free float{{cite:chatcmpltool}}. Academic literature and UBS’s own analysis find no consistent relationship between changes in IPO activity and forward market returns; the stronger historical pattern is that IPO activity is a coincident indicator — issuance rises when markets are strong and falls when conditions weaken{{cite:chatcmpltool}}.

Goldman Sachs projected in February that U.S. IPO proceeds would quadruple to a record $160 billion in 2026 as dealmaking rebounds{{cite:chatcmpltool}}. The H1 run rate — $114.7 billion already raised through 82 deals — puts the year comfortably on pace to meet or exceed that forecast, particularly if SK hynix prices at the top of its range.

Follow-Ons, Convertibles, and the Sponsor Exit Wave

IPOs are the visible part of the issuance story, but follow-ons and convertibles are doing the heavy lifting. Q1 follow-on proceeds reached $42 billion, with private equity sponsors accounting for an estimated 67% of March volume as vintage 2017–2020 funds press for LP liquidity{{cite:chatcmpltool}}. Secondary selling reached $20.3 billion in Q1 alone, including $13.3 billion in March{{cite:chatcmpltool}}.

Convertible issuance is running at approximately twice the 2025 pace, with $34 billion priced through April, and roughly half of that issuance is AI-linked — anchored by Oracle’s $5 billion mandatory convertible preferred and CoreWeave’s $4 billion deal{{cite:chatcmpltool}}. Convertible issuers are effectively locking in favorable terms while the VIX sits near 16.76 and the 10-year Treasury yield has pulled back to 4.59% from a March peak of 4.92%{{cite:chatcmpltool}}. Those conditions may not persist if the Fed under Chair Kevin Warsh signals a more restrictive posture.

Sector Rotation Within the IPO Class

The IPO market is differentiating sharply by sector. Healthcare anchored Q1 with 7 deals and +43.6% average returns — 6 biotech IPOs versus just 7 in all of 2025 — but rotated to -6.2% year-to-date in Q2 as capital migrated toward AI{{cite:chatcmpltool}}. Technology staged a dramatic reversal: +16.7% YTD after -5.8% in Q1, led by Cerebras Systems’ $5.55 billion IPO on May 13, the largest AI-chip IPO on record{{cite:chatcmpltool}}. Industrials carrying the AI-power nexus — Forgent Power ($1.5B) and Fervo Energy ($1.89B) — reflect a world structurally short on electricity{{cite:chatcmpltool}}.

Financials were absent in Q1, but Kraken and Plaid (together roughly $8 billion) sit in the Q2/Q3 pipeline{{cite:chatcmpltool}}. The breadth of the pipeline — semiconductors, fintech, healthcare, energy infrastructure — is itself a signal. When issuance concentrates in a single theme, it tends to be late-cycle. When it broadens across sectors, it is more consistent with a durable reopening.

Lockup Calendar: Unlocking Events to Track

The MiniMax unlock on July 9 is a smaller-scale but instructive analog: a recent Hong Kong listing facing its first insider release, with strategic investors Alibaba and miHoYo publicly pledging to hold{{cite:chatcmpltool}}. Public pledges of support are not binding sales restrictions, but they do signal coordination around the unlock — a pattern worth noting as SpaceX’s December 8 expiration approaches.

The Liquidity Backdrop: Constructive but Watch the Crowding

Citadel Securities’ Scott Rubner described the defining story of 2026 as “the structural transformation of equity markets” rather than any single macro event{{cite:chatcmpltool}}. June 2026 recorded approximately $150 billion in U.S. equity inflows, the largest single-month figure on record{{cite:chatcmpltool}}. Barclays analyst Emmanuel Cau flagged this as a FOMO-driven crowding signal that could cap upside and amplify downside risk heading into Q2 earnings season{{cite:chatcmpltool}}.

On the buyback side, new programs continue to enter. Aegon began a EUR 200 million buyback on July 1, following completion of a EUR 227 million program{{cite:chatcmpltool}}. Third Coast Bancshares announced a 2026 share repurchase program on July 2{{cite:chatcmpltool}}. TON Strategy (TONX) entered a Rule 10b5-1 plan to repurchase stock under its existing $250 million authorization{{cite:chatcmpltool}}. Cosmos Health expanded its buyback to 3.42 million shares{{cite:chatcmpltool}}. Currys launched a GBP 50 million buyback program{{cite:chatcmpltool}}. Diversified Energy continues repurchasing under its existing program{{cite:chatcmpltool}}.

None of these individually moves the needle against $1.2 trillion in trailing buybacks, but they confirm the directional flow: corporations remain net buyers of equity even as the IPO market floods the primary side with new supply.

What to Watch Next

1. SK hynix pricing (July 10). Whether the deal prices at the top of its range and how the ADR trades in its first sessions will set the tone for large-cap international listings for the remainder of the year. A deal this size absorbing cleanly would validate the market’s capacity for mega-issuance.

2. SpaceX Q2 earnings (late July–August). The first post-IPO earnings report opens the initial selling window for non-Musk insiders. The stock’s reaction — and whether insider selling materializes — will be the first real liquidity test for the largest debut in history.

3. Fed signaling under Chair Warsh. Funds sit at 3.50–3.75% and the 10-year at 4.59%{{cite:chatcmpltool}}. Convertible issuance, which is running at 2x the 2025 pace, is the most rate-sensitive segment of ECM. A hawkish pivot could tighten that window quickly.

4. SPAC liquidation wave. With 352 active SPACs and redemption rates above 95%, the gap between institutional-grade and speculative vehicles is widening. Watch for extension filings and trust liquidations in Q3, which would redirect capital rather than destroy it.

5. Kraken and Plaid IPOs. If either fintech prices in Q3, it would mark the first meaningful financial-sector issuance of 2026 and test whether investor appetite extends beyond AI and healthcare.

The base case — roughly 45% probability in ArcStone’s scenario framework — is managed volatility: Iran stalemate persists, tariffs hold steady, Warsh maintains continuity, and earnings stay strong, allowing ECM activity to front-load into windows with healthcare and industrial/AI IPOs dominating the calendar{{cite:chatcmpltool}}. The bull case (35%) sees 60+ U.S. deals and $55–65 billion in annual IPO proceeds if the Iran ceasefire holds and AI monetization accelerates. The bear case (20%) envisions an exogenous shock — Iran re-escalation, a hawkish Warsh pivot, or an earnings miss — that freezes the IPO market as in H1 2022{{cite:chatcmpltool}}.

The trajectory is clear: issuance is running at its fastest pace in five years, the pipeline is deep, and the buyback machine is large enough to keep net supply shrinking. The 60/40 lean is toward a constructive H2 — but the 40% carries real weight, and a single geopolitical or policy shock could close the window as fast as it opened.